SCHEMBL3769112

SCHEMBL3769112

O=C(CN1CCN(c2ccccc2Cl)CC1)N1CCN(C2CCCCC2)CC1

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.55
KMT2A Q03164 3/20 0.55
TP53 P04637 1/20 0.55
ALOX15 P16050 1/20 0.55
TSHR P16473 1/20 0.55
MAPK1 P28482 1/20 0.55
HSD17B10 Q99714 1/20 0.55
ALDH1A1 P00352 5/20 0.52
KDM4E B2RXH2 4/20 0.52
POLB P06746 1/20 0.52
HTR7 P34969 1/20 0.51
MAPT P10636 2/20 0.50
HRH3 Q9Y5N1 4/20 0.48
PARP1 P09874 1/20 0.48
DRD2 P14416 1/20 0.47
DRD3 P35462 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
GRM5 P41594 1/20 0.47
LMNA P02545 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13004961 0.99 MEN1 (0.54) MEN1KMT2ATP53ALOX15TSHR
SCHEMBL3767597 0.96 HTR7 (0.52) MEN1KMT2ATP53ALOX15TSHR
SCHEMBL3772593 0.91 DRD2 (0.51) MEN1KMT2ATP53ALOX15TSHR
SCHEMBL3769002 0.89 DRD2 (0.50) MEN1KMT2ATSHRHTR7DRD2
SCHEMBL3770906 0.87 ALDH1A1 (0.57) MEN1KMT2ATP53ALOX15TSHR
SCHEMBL3763088 0.87 TSHR (0.58) MEN1KMT2ATP53ALOX15TSHR
SCHEMBL20122620 0.87 TSHR (0.58) MEN1KMT2ATP53ALOX15TSHR
SCHEMBL3774214 0.86 TSHR (0.56) MEN1KMT2ATP53ALOX15TSHR
SCHEMBL13004958 0.86 KMT2A (0.56) MEN1KMT2ATP53ALOX15TSHR
SCHEMBL3767578 0.84 ALDH1A1 (0.72) MEN1KMT2AALOX15MAPK1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
WO-2007016496-A2 DIPIPERAZINYL KETONES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049571-A1 Dipiperazinyl ketones and related analogues HRH4, HRH3, HRH1 MEN1 3270/4885KMT2A 242/4885TP53 3661/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.